Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18432567 | METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDR | February 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18425859 | METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDR | January 2024 | August 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18575650 | ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND APPLICATION THEREOF | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18396466 | METHODS OF MANUFACTURING DIMERIC ANTIBODIES | December 2023 | July 2024 | Allow | 7 | 1 | 0 | No | No |
| 18396418 | DIMERIC ANTIBODIES | December 2023 | July 2024 | Allow | 7 | 1 | 0 | No | No |
| 18503245 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODIES AND METHODS OF USING THE SAME | November 2023 | July 2024 | Allow | 8 | 1 | 0 | No | No |
| 18314091 | Antigen Binding Molecules Targeting SARS-CoV-2 | May 2023 | October 2023 | Abandon | 6 | 1 | 0 | No | No |
| 18313306 | Antigen Binding Molecules Targeting SARS-CoV-2 | May 2023 | December 2023 | Allow | 7 | 1 | 0 | No | No |
| 18061533 | ANTIGEN-BINDING PROTEIN AND USE THEREOF | December 2022 | March 2023 | Allow | 3 | 0 | 0 | No | No |
| 17821182 | LYMPHOCYTES-ANTIGEN PRESENTING CELLS CO-STIMULATORS AND USES THEREOF | August 2022 | March 2023 | Allow | 7 | 0 | 1 | Yes | No |
| 17809409 | COMPOSITIONS AND METHODS FOR TREATING HER2 POSITIVE CANCERS | June 2022 | April 2023 | Allow | 9 | 1 | 0 | No | No |
| 17834497 | ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS | June 2022 | July 2023 | Allow | 13 | 1 | 0 | Yes | No |
| 17499687 | ANTI TRBC1 ANTIGEN BINDING DOMAINS | October 2021 | April 2022 | Allow | 6 | 1 | 0 | No | No |
| 17484452 | IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | September 2021 | May 2022 | Allow | 7 | 1 | 0 | No | No |
| 17478370 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17477889 | ANTI-PD-1 ANTIBODIES AND USES THEREOF | September 2021 | February 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17471271 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | September 2021 | February 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17471206 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | September 2021 | August 2022 | Allow | 11 | 1 | 0 | No | No |
| 17402300 | LYM-1 AND LYM-2 ANTIBODY COMPOSITIONS AND IMPROVED CAR CONSTRUCTS | August 2021 | March 2022 | Allow | 7 | 0 | 0 | Yes | No |
| 17391888 | CD47 ANTIBODIES AND METHODS OF USE THEREOF | August 2021 | January 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17353087 | ANTIBODIES | June 2021 | December 2023 | Allow | 30 | 0 | 0 | Yes | No |
| 17352652 | CELL INJURY INDUCING THERAPEUTIC DRUG FOR USE IN CANCER THERAPY | June 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17311591 | METHODS OF USING TUMOR INFILTRATING LYMPHOCYTES IN DOUBLE-REFRACTORY MELANOMA | June 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17327170 | ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS TO TREAT METABOLIC DISORDERS | May 2021 | November 2024 | Allow | 41 | 1 | 0 | No | No |
| 17309252 | HUMANIZED ANTI-HUMAN PD-L1 MONOCLONAL ANTIBODY AND PREPARATION METHOD THEREFOR AND USE THEREOF | May 2021 | July 2024 | Allow | 38 | 1 | 1 | No | No |
| 17306241 | Antigen-Binding Constructs Targeting HER2 | May 2021 | October 2024 | Allow | 41 | 1 | 1 | No | No |
| 17289244 | NOVEL METHOD FOR PRODUCING ANTIBODIES | April 2021 | February 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17288845 | T CELLS WITH SUICIDE SWITCH | April 2021 | February 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17287828 | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES | April 2021 | January 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17228023 | ANTIBODIES | April 2021 | July 2021 | Allow | 3 | 1 | 0 | No | No |
| 17225273 | CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17223935 | Multi-Specific Molecules | April 2021 | February 2022 | Allow | 10 | 2 | 0 | Yes | No |
| 17203291 | CANNABINOID RECEPTOR TYPE 1 (CB1) BINDING PROTEINS AND USES THEREOF | March 2021 | November 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 17199258 | ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSICAL HLA-I AND NEOANTIGEN AND THEIR METHODS OF USE | March 2021 | December 2023 | Allow | 34 | 1 | 0 | No | No |
| 17187074 | CHIMERIC ANTIGEN RECEPTORS AND METHODS OF MAKING | February 2021 | April 2024 | Allow | 37 | 1 | 0 | No | No |
| 17250725 | PEPTIDE VACCINES | February 2021 | February 2023 | Allow | 23 | 0 | 0 | Yes | No |
| 17170854 | NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF | February 2021 | November 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17248367 | TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTI-CANCER AGENT | January 2021 | December 2024 | Abandon | 46 | 2 | 0 | No | No |
| 17150884 | ANTIBODY THERAPEUTICS THAT BIND CD123 | January 2021 | April 2023 | Allow | 27 | 0 | 0 | No | No |
| 17148450 | Antigen Binding Proteins that Bind PD-L1 | January 2021 | October 2023 | Allow | 33 | 0 | 0 | No | No |
| 17260213 | HEAVY CHAIN ANTIBODIES BINDING TO CD19 | January 2021 | September 2024 | Allow | 44 | 2 | 0 | No | No |
| 17116822 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | December 2020 | May 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17116835 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | December 2020 | May 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17107302 | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF | November 2020 | February 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17059745 | CAR T CELLS THAT TARGET B-CELL ANTIGENS | November 2020 | March 2024 | Allow | 40 | 1 | 1 | No | No |
| 17058794 | Biomarkers for determining the effectiveness of immune checkpoint inhibitors | November 2020 | July 2024 | Allow | 44 | 2 | 1 | No | No |
| 17100428 | Sialylated Glycoproteins | November 2020 | September 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17098180 | COMBINATION OF IMMUNOTHERAPY WITH LOCAL CHEMOTHERAPY FOR THE TREATMENT OF MALIGNANCIES | November 2020 | June 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 17054994 | NOVEL LEUCINE-RICH REPEAT NEURONAL PROTEIN 1 (LRRN1) ANTIBODIES AND USES THEREOF | November 2020 | April 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17054670 | CHIMERIC ANTIGEN RECEPTOR | November 2020 | December 2023 | Allow | 37 | 1 | 0 | No | No |
| 17092817 | VISTA Antagonist and Methods of Use | November 2020 | January 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17088765 | ANTI-CD37 ANTIBODIES | November 2020 | November 2023 | Abandon | 37 | 1 | 0 | No | No |
| 17077376 | ANTIBODIES | October 2020 | January 2021 | Allow | 3 | 0 | 0 | No | No |
| 17033452 | Sialylated Glycoproteins | September 2020 | September 2023 | Abandon | 36 | 1 | 0 | No | No |
| 17032994 | Sialylated Glycoproteins | September 2020 | September 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16997757 | METHOD FOR DECREASING IMMUNOGENICITY | August 2020 | February 2024 | Abandon | 42 | 0 | 1 | No | No |
| 16994065 | MATERIALS AND METHODS FOR IMPROVED SINGLE CHAIN VARIABLE FRAGMENTS | August 2020 | June 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 16986913 | CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF | August 2020 | September 2024 | Allow | 49 | 3 | 0 | Yes | No |
| 16986214 | Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies | August 2020 | June 2024 | Allow | 46 | 3 | 0 | Yes | No |
| 16942531 | THERAPEUTIC CD47 ANTIBODIES | July 2020 | June 2023 | Abandon | 35 | 1 | 0 | No | No |
| 16965287 | COMBINATION THERAPY USING ADOPTIVE CELL THERAPY AND CHECKPOINT INHIBITOR | July 2020 | February 2025 | Abandon | 55 | 2 | 1 | Yes | No |
| 16963091 | ANTI-CD73 ANTI-PD-L1 BISPECIFIC ANTIBODIES | July 2020 | February 2021 | Allow | 7 | 2 | 0 | No | No |
| 16962755 | Regulatory T Cell Expressing a Chimeric Antigen Receptor | July 2020 | August 2024 | Allow | 49 | 2 | 1 | No | No |
| 16927339 | Antibodies Directed Against Programmed Death-1(PD-1) | July 2020 | August 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16927947 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | July 2020 | June 2023 | Allow | 35 | 1 | 0 | Yes | No |
| 16927675 | TREATMENT OF BRAIN CANCERS USING CENTRAL NERVOUS SYSTEM MEDIATED GENE TRANSFER OF MONOCLONAL ANTIBODIES | July 2020 | June 2024 | Allow | 47 | 4 | 1 | Yes | No |
| 16926355 | ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSICAL HLA-I AND NEOANTIGEN AND THEIR METHODS OF USE | July 2020 | January 2021 | Allow | 6 | 0 | 1 | Yes | No |
| 16925980 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | July 2020 | July 2023 | Allow | 36 | 1 | 0 | No | No |
| 16919846 | ANTI-PD-1 ANTIBODIES AND USES THEREOF | July 2020 | April 2021 | Allow | 10 | 1 | 1 | No | No |
| 16919020 | THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING MOLECULES AND METHODS OF USING THE MOLECULES | July 2020 | November 2022 | Allow | 29 | 0 | 0 | No | No |
| 16956807 | ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY RECOGNIZES B CELL MALIGNANCIES, CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME, AND USES THEREOF | June 2020 | May 2023 | Allow | 34 | 1 | 0 | No | No |
| 16770019 | METHODS FOR ENHANCING AND MAINTAINING CAR-T CELL EFFICACY | June 2020 | June 2024 | Abandon | 49 | 1 | 1 | No | No |
| 16769867 | T-CELLS COMPRISING TWO DIFFERENT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | June 2020 | July 2024 | Allow | 49 | 2 | 1 | No | No |
| 16768575 | METHODS FOR DOSING AND FOR MODULATION OF GENETICALLY ENGINEERED CELLS | May 2020 | October 2023 | Abandon | 41 | 1 | 0 | No | No |
| 16767470 | ANTI-CD33 AND ANTI-CD7 COMBINATION TREATMENT | May 2020 | June 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16877150 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES | May 2020 | November 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16763784 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | May 2020 | March 2022 | Allow | 22 | 0 | 1 | No | No |
| 16872158 | ANTI-PD-L1 ANTIBODIES AND DIAGNOSTIC USES THEREOF | May 2020 | August 2022 | Allow | 27 | 1 | 0 | No | No |
| 16759490 | MOLECULAR SWITCH-MEDIATED CONTROL OF ENGINEERED CELLS | April 2020 | September 2023 | Allow | 41 | 2 | 1 | No | No |
| 16851691 | ANTIBODIES AGAINST 4G7-DERIVED CHIMERIC ANTIGEN RECEPTORS | April 2020 | March 2023 | Allow | 35 | 1 | 0 | No | No |
| 16844759 | NUCLEIC ACID MOLECULES ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND USES THEREOF | April 2020 | June 2020 | Allow | 2 | 0 | 0 | No | No |
| 16840153 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | April 2020 | December 2022 | Allow | 32 | 2 | 0 | Yes | No |
| 16821551 | CHIMERIC ANTIGEN RECEPTORS FOR PHAGOCYTOSIS | March 2020 | March 2021 | Allow | 12 | 0 | 0 | Yes | No |
| 16819778 | COMPOSITIONS AND METHODS FOR TREATING DISEASES | March 2020 | August 2022 | Abandon | 29 | 1 | 0 | No | No |
| 16813167 | ANTIBODIES | March 2020 | January 2025 | Abandon | 59 | 5 | 1 | No | Yes |
| 16645290 | UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T-CELL PREPARATION TECHNIQUE | March 2020 | April 2024 | Allow | 49 | 1 | 1 | No | No |
| 16787931 | METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES | February 2020 | September 2023 | Abandon | 44 | 1 | 0 | No | No |
| 16784170 | CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS | February 2020 | June 2023 | Abandon | 40 | 1 | 0 | No | No |
| 16777053 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF | January 2020 | August 2023 | Allow | 42 | 1 | 0 | No | No |
| 16773927 | BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1 | January 2020 | October 2022 | Abandon | 33 | 1 | 0 | No | No |
| 16632091 | CHIMERIC ANTIGEN RECEPTORS WITH ENHANCED NFKB SIGNALING | January 2020 | July 2022 | Allow | 30 | 2 | 0 | No | No |
| 16622636 | COMPOSITIONS AND METHODS TARGETING COMPLEMENT COMPONENT 3 FOR INHIBITING TUMOR GROWTH | December 2019 | September 2023 | Allow | 45 | 2 | 1 | No | No |
| 16620370 | ANTI TRBC1 ANTIGEN BINDING DOMAINS | December 2019 | April 2022 | Allow | 28 | 1 | 0 | No | No |
| 16703484 | THERAPEUTIC CD47 ANTIBODIES | December 2019 | October 2022 | Allow | 35 | 2 | 0 | No | No |
| 16611772 | METHODS TO AUGMENT OR ALTER SIGNAL TRANSDUCTION | November 2019 | April 2024 | Abandon | 53 | 1 | 1 | No | No |
| 16608362 | CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND SECONDARY EFFECTORS AND USES THEREOF | October 2019 | September 2022 | Abandon | 35 | 0 | 1 | No | No |
| 16663583 | ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF | October 2019 | June 2023 | Allow | 43 | 2 | 1 | No | Yes |
| 16608336 | CHIMERIC ANTIBODY/T-CELL RECEPTOR CONSTRUCTS AND USES THEREOF | October 2019 | December 2022 | Allow | 37 | 1 | 1 | No | No |
| 16659797 | ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF | October 2019 | October 2022 | Allow | 36 | 1 | 1 | No | No |
| 16658480 | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF | October 2019 | June 2023 | Abandon | 44 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROARK, JESSICA HOPE.
With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ROARK, JESSICA HOPE works in Art Unit 1643 and has examined 652 patent applications in our dataset. With an allowance rate of 60.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner ROARK, JESSICA HOPE's allowance rate of 60.0% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ROARK, JESSICA HOPE receive 1.83 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ROARK, JESSICA HOPE is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +32.7% benefit to allowance rate for applications examined by ROARK, JESSICA HOPE. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.0% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 46.3% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 71.4% of appeals filed. This is in the 53% percentile among all examiners. Of these withdrawals, 73.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 68.4% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 48% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 56% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.